1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Use este identificador para citar o ir al link de este elemento: http://hdl.handle.net/1843/48244
Registro completo de metadatos
Campo DCValorIdioma
dc.creatorAmanda Leal Rochapt_BR
dc.creatorAdalberto Luiz Rosapt_BR
dc.creatorSandra Yasuyo Fukadapt_BR
dc.creatorGisele Assis Castro Goulartpt_BR
dc.creatorDaniel Dias Ribeiropt_BR
dc.creatorLucas Guimarães Abreupt_BR
dc.creatorTarcília Aparecida da Silvapt_BR
dc.creatorRayana Longo Bighetti-Trevisanpt_BR
dc.creatorLetícia Fernanda Dufflespt_BR
dc.creatorJosé Alcides Almeida de Arrudapt_BR
dc.creatorThaise Mayumi Tairapt_BR
dc.creatorBruna Rodrigues Dias Assispt_BR
dc.creatorSoraia Macaript_BR
dc.creatorIvana Márcia Alves Dinizpt_BR
dc.creatorMarcio Mateus Belotipt_BR
dc.date.accessioned2022-12-20T14:17:48Z-
dc.date.available2022-12-20T14:17:48Z-
dc.date.issued2020-02-
dc.citation.volume186pt_BR
dc.citation.spage45pt_BR
dc.citation.epage53pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.thromres.2019.12.014pt_BR
dc.identifier.issn00493848pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/48244-
dc.description.resumoIntroduction: Anticoagulants are widely used in orthopedic surgery to decrease the risk of deep vein thrombosis. While significant bone impairment is induced by long-term heparin therapy, little is known about the effects of direct oral anticoagulants (DOACs). Herein, we investigated the effects of dabigatran etexilate (Pradaxa®), a DOAC inhibitor of thrombin, on bone cells using in vitro and ex vivo cell culture models. Materials and methods: Osteoblasts and osteoclasts exposed to different concentrations of dabigatran etexilate and untreated cells were assayed for cell differentiation and activity. Favorable osteogenic conditions for osteoblasts were tested using titanium with nanotopography (Ti-Nano). In addition, mice treated with a dabigatran etexilate solution had bone marrow cells analyzed for the ability to generate osteoclasts. Results: Dabigatran etexilate at concentrations of 1 μg/mL and 2 μg/mL did not impact osteoclast or osteoblast viability. The drug inhibited osteoclast differentiation and activity as observed by the reduction of TRAP+ cells, resorption pits and gene and protein expression of cathepsin K. Consistently, osteoclasts from mice treated with dabigatran showed decreased area, resorptive activity, as well as gene and protein expression of cathepsin K. In osteoblast cultures, grown both on polystyrene and Ti-Nano, dabigatran etexilate reduced alkaline phosphatase (ALP) activity, matrix mineralization, gene expression of ALP and osteocalcin. Conclusions: Dabigatran etexilate inhibited osteoclast differentiation in ex vivo and in vitro models in a dose-dependent manner. Moreover, the drug reduced osteoblast activity even under optimal osteogenic conditions. This study provides new evidence regarding the negative overall impact of DOACs on bone cells.pt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAO - DEPARTAMENTO DE ODONTOLOGIA RESTAURADORApt_BR
dc.publisher.departmentFAO - DEPARTAMENTO DE ODONTOPEDIATRIA E ORTODONTIApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofThrombosis Researchpt_BR
dc.rightsAcesso Restritopt_BR
dc.subjectAnticoagulantspt_BR
dc.subject.otherAnticoagulantspt_BR
dc.subject.otherDabigatranpt_BR
dc.subject.otherThrombinpt_BR
dc.subject.otherOsteoclastspt_BR
dc.subject.otherOsteoblastspt_BR
dc.subject.otherCellspt_BR
dc.subject.otherCathepsin Kpt_BR
dc.titleInhibitory effects of dabigatran etexilate, a direct thrombin inhibitor, on osteoclasts and osteoblastspt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.sciencedirect.com/science/article/pii/S004938481930547X?via%3Dihubpt_BR
Aparece en las colecciones:Artigo de Periódico

archivos asociados a este elemento:
no existem archivos asociados a este elemento.
Mostrar registro simple del elemento Visualizar estadísticas


Los elementos en el repositorio están protegidos por copyright, con todos los derechos reservados, salvo cuando es indicado lo contrario.